CALU Antibody

What is CALU (Calumenin) and what is its biological function?

CALU (Calumenin) is a calcium-binding protein predominantly localized in the endoplasmic reticulum (ER). It belongs to the family of multiple EF-hand proteins (CERC) that include reticulocalbin, ERC-55, and Cab45. The protein is involved in essential ER functions such as protein folding and sorting. Multiple alternatively spliced transcript variants encoding different isoforms of CALU have been identified in the human genome .

The biological significance of CALU extends beyond its structural role, as emerging research suggests its involvement in multiple cellular processes. As a calcium-binding protein, it likely participates in calcium-dependent signaling pathways and may influence calcium homeostasis within the ER. The protein's molecular weight is approximately 37 kDa (calculated), though observed molecular weights in experimental conditions typically range from 47-50 kDa, suggesting post-translational modifications .

What types of CALU antibodies are available for research?

Several types of CALU antibodies are available for research applications, primarily categorized by their production method and host species:

Polyclonal antibodies recognize multiple epitopes of the CALU protein and are available in various formats targeting different regions of the protein, including full-length (AA 1-315), internal regions, and C-terminal segments (AA 216-246 or AA 217-246) . These antibodies offer high sensitivity but may show more batch-to-batch variation.

Monoclonal antibodies provide higher specificity for particular epitopes and demonstrate greater consistency between batches. The mouse monoclonal antibody 67585-1-Ig, for example, has been validated for multiple applications including Western blot, immunohistochemistry, and immunofluorescence .

What are the common applications for CALU antibodies in research?

CALU antibodies are utilized across multiple experimental techniques in research settings:

For Western blotting applications, CALU antibodies typically detect bands at 47-50 kDa, though some isoforms may appear at different molecular weights. When performing immunohistochemistry, antigen retrieval is generally recommended using TE buffer pH 9.0 or alternatively citrate buffer pH 6.0 .

Immunofluorescence applications have successfully detected CALU in various cell lines including HeLa cells, providing insights into subcellular localization patterns. The recommended dilution ranges should be optimized for each specific experimental system to obtain optimal results .

How should CALU antibodies be stored and handled for optimal performance?

Proper storage and handling of CALU antibodies are crucial for maintaining their reactivity and specificity:

• Storage Temperature: Store at -20°C for long-term preservation. Antibodies are generally stable for one year after shipment when stored properly .

• Buffer Composition: Most CALU antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain stability during freeze-thaw cycles .

• Aliquoting: For larger volume antibodies, aliquoting is recommended to avoid repeated freeze-thaw cycles, though some manufacturers note that aliquoting is unnecessary for -20°C storage for their specific formulations .

• Safety Precautions: Note that these antibodies contain sodium azide, which is toxic. Appropriate laboratory safety protocols should be followed when handling these reagents .

• Working Solutions: When preparing working dilutions, use fresh buffer and prepare only the amount needed for immediate use. Working solutions should generally be used within 24 hours and kept at 4°C during this time.

What is the role of CALU in cancer development and progression?

CALU has emerged as a significant factor in cancer biology. Analysis of TCGA datasets has revealed that the CALU co-expressed gene network is markedly altered in human colon (COAD) and lung (LUAD) cancers . This suggests a potential role for CALU in the molecular pathways underlying cancer development.

Research has demonstrated that cancer cases with abnormal expression of CALU (along with AURKA and MCM2) had significantly lower survival rates compared to other patients. Protein level analyses comparing healthy samples with early and advanced tumors showed increased expression of CALU through normal-carcinoma transition in both colon and lung cancers .

The increased expression of CALU in cancer tissues makes it valuable as a potential biomarker for diagnostic applications. Furthermore, its altered expression pattern suggests it may be functionally involved in tumor progression, possibly through its calcium-binding properties and role in protein folding within the endoplasmic reticulum - processes often dysregulated in cancer cells.

How does CALU interact with AURKA and MCM2 in cancer biology?

The interaction between CALU, Aurora Kinase A (AURKA), and Minichromosome Maintenance Complex Component 2 (MCM2) represents an important molecular axis in cancer development. Research has established that a gene panel consisting of these three genes can successfully distinguish cancer tumors from healthy samples .

Mechanistically, the relationship between these proteins appears biologically significant:

• CALU functions in calcium-dependent processes and protein folding in the ER

• AURKA is a serine/threonine kinase involved in mitotic cell division

• MCM2 is essential for DNA replication and genomic stability

The coordinated expression and function of these proteins may contribute to cancer development through multiple mechanisms:

• Dysregulation of calcium signaling (via CALU)

• Abnormal cell division (via AURKA)

• Disrupted DNA replication control (via MCM2)

In experimental settings, all three proteins showed increased levels during normal-carcinoma transition in both colon and lung cancers. Western blot analyses using anti-CALU (4C6) Mouse mAb (#11991S), anti-Aurora A (D3E4Q) Rabbit mAb (#14475S), and anti-MCM2 Antibody (#4007S) demonstrated this coordinated upregulation .

These findings suggest that the interactions between CALU, AURKA, and MCM2 have a pivotal role in cancer development, warranting further exploration of their molecular interplay and potential as therapeutic targets.

What are the considerations for using CALU antibodies in multiplexed immunofluorescence assays?

When designing multiplexed immunofluorescence assays incorporating CALU antibodies, several important considerations must be addressed:

• Antibody Species Compatibility: Choose primary antibodies raised in different host species to avoid cross-reactivity. For CALU, both rabbit polyclonal (e.g., ABIN7007789) and mouse monoclonal (e.g., 67585-1-Ig) antibodies are available, allowing flexibility in experimental design .

• Isotype Selection: When using multiple antibodies from the same host species, select different isotypes. For instance, mouse monoclonal CALU antibodies are typically IgG1, which should be paired with antibodies of different isotypes to allow isotype-specific secondary antibodies .

• Dilution Optimization: CALU antibodies for immunofluorescence applications typically require dilutions between 1:50-1:500. In multiplexed assays, each antibody must be individually titrated to achieve optimal signal-to-noise ratios without overwhelming other signals .

• Spectral Separation: Select secondary antibodies or direct conjugates with fluorophores that have minimal spectral overlap to avoid bleed-through during imaging.

• Sequential Staining Protocols: In some cases, sequential staining rather than coincubation may be necessary, especially when studying CALU alongside other ER proteins that may have overlapping subcellular localization.

• Validation Controls: Include appropriate controls for each antibody in the panel, including single-stained samples to verify specificity and absence of cross-reactivity between antibodies.

How can I optimize Western blot protocols for detecting different isoforms of CALU?

Optimizing Western blot protocols for detecting different CALU isoforms requires attention to several technical aspects:

• Gel Percentage Selection: Use lower percentage gels (8-10% acrylamide) to better separate high molecular weight isoforms or gradient gels (4-15%) to visualize multiple isoforms simultaneously. Standard observed molecular weights for CALU range from 47-57 kDa, though some isoforms may appear at different weights .

• Sample Preparation:

  • Total protein extraction using RIPA buffer with protease inhibitors

  • For membrane-associated isoforms, consider specialized extraction buffers

  • Include phosphatase inhibitors if studying phosphorylated forms of CALU

• Antibody Selection: Choose antibodies that target conserved regions to detect multiple isoforms, or isoform-specific antibodies for targeted detection. Antibodies targeting different epitopes include those recognizing AA 1-315 (full-length), AA 20-315, or C-terminal regions (AA 216-246 or AA 217-246) .

• Dilution Optimization:

  • For WB applications, recommended dilutions range from 1:500-1:4000

  • Optimize primary antibody incubation time (typically overnight at 4°C)

  • Secondary antibody selection: Anti-Rabbit IgG, HRP-linked Antibody for rabbit primary antibodies or Anti-Mouse IgG, HRP-linked Antibody for mouse primary antibodies

• Detection System: Use high-sensitivity ECL reagents for detecting low-abundance isoforms. For quantification of different isoforms, consider digital imaging systems for densitometry analysis using software like ImageJ .

• Loading Controls: Include appropriate loading controls (β-actin is commonly used) and normalize band intensities for accurate comparison between samples .

How do I validate the specificity of a CALU antibody?

Validating the specificity of CALU antibodies is essential for ensuring reliable experimental results. A comprehensive validation approach should include:

• Positive Control Samples: Use cell lines or tissues known to express CALU, such as HeLa, HEK-293, HepG2, and Jurkat cells, which have been confirmed to express CALU at detectable levels .

• Knockout/Knockdown Validation:

  • Generate CALU knockout cell lines using CRISPR-Cas9

  • Alternatively, use siRNA to knockdown CALU expression

  • Compare antibody reactivity between wildtype and KO/KD samples

• Multiple Antibody Comparison: Test multiple antibodies targeting different epitopes of CALU to confirm consistent detection. Options include full-length antibodies (AA 1-315) and those targeting specific regions like the C-terminus (AA 216-246) .

• Peptide Competition Assay: Pre-incubate the antibody with excess immunizing peptide to block specific binding. Disappearance of signal in this condition confirms specificity.

• Western Blot Analysis: Verify that the antibody detects a band of the expected molecular weight (typically 47-50 kDa for CALU, though some isoforms may vary) .

• Cross-Species Reactivity: If working with animal models, confirm the antibody's reactivity across species. Many CALU antibodies show reactivity with human, mouse, and rat samples, but this should be verified experimentally .

• Application-Specific Validation: For each experimental technique (WB, IHC, IF), perform specific validation tests appropriate for that method.

What are the challenges in using CALU antibodies for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) studies with CALU antibodies present several challenges that researchers should address:

• Antibody Binding Efficiency: Not all CALU antibodies are suitable for immunoprecipitation. While some antibodies like the anti-Calumenin (CALU) (AA 20-315) antibody have been validated for IP applications, many others have not been specifically tested for this purpose .

• Buffer Optimization: CALU is a calcium-binding protein, so buffer conditions are critical:

  • Consider calcium concentration in lysis and wash buffers

  • Test different detergent strengths (0.1-1% NP-40 or Triton X-100)

  • Include protease inhibitors to prevent degradation

• Cross-linking Consideration: For weakly interacting partners, consider using membrane-permeable cross-linking agents before lysis to stabilize protein complexes.

• Control Experiments:

  • Include IgG control from the same species as the CALU antibody

  • Perform reverse Co-IP when studying specific interaction partners

  • Include input controls representing a fraction of the starting material

• Detection Methods: For Western blot detection after Co-IP:

  • Use HRP-conjugated protein A/G to minimize detection of IP antibody heavy chains

  • Consider using antibodies raised in different host species for IP and WB

• Subcellular Fractionation: Since CALU is primarily localized to the ER, consider performing subcellular fractionation before IP to enrich for ER proteins and reduce non-specific binding.

• Validation of Interactions: Confirm interactions identified by Co-IP using complementary methods such as proximity ligation assay or fluorescence resonance energy transfer (FRET) to validate physiological relevance.

How can I troubleshoot non-specific binding when using CALU antibodies in IHC applications?

Non-specific binding is a common challenge in immunohistochemistry applications. When using CALU antibodies for IHC, consider these troubleshooting strategies:

• Optimization of Antigen Retrieval:

  • Test both recommended methods: TE buffer pH 9.0 and citrate buffer pH 6.0

  • Adjust retrieval time and temperature based on tissue type

  • For formalin-fixed tissues, longer retrieval times may be necessary

• Blocking Protocol Adjustment:

  • Increase blocking time (30-60 minutes)

  • Try different blocking agents (BSA, normal serum, commercial blocking solutions)

  • Consider adding 0.1-0.3% Triton X-100 for better penetration

• Antibody Dilution Optimization:

  • Perform a dilution series (e.g., 1:50, 1:100, 1:250, 1:500, 1:1000)

  • Adjust incubation time and temperature (overnight at 4°C vs. 1-2 hours at room temperature)

• Washing Stringency:

  • Increase number of wash steps

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Extend washing time between antibody incubations

• Secondary Antibody Considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Dilute secondary antibodies appropriately (typically 1:200-1:500)

  • Consider switching to polymer-based detection systems for improved sensitivity and reduced background

• Tissue-Specific Adaptations:

  • For tissues with high endogenous peroxidase activity, enhance quenching steps

  • For tissues with high biotin content, use biotin-free detection systems

  • Consider tissue-specific fixation protocols for optimal epitope preservation

• Controls:

  • Include negative controls (omitting primary antibody)

  • Use tissue known to be negative for CALU as additional control

  • Include positive controls with established CALU expression (e.g., human placenta tissue)

How can CALU antibodies be used to study endoplasmic reticulum stress responses?

CALU's localization in the endoplasmic reticulum makes CALU antibodies valuable tools for studying ER stress responses:

• Colocalization Studies: CALU antibodies can be used in dual immunofluorescence studies to examine colocalization with established ER stress markers such as BiP/GRP78, CHOP, or XBP1. For such applications, mouse monoclonal CALU antibody (67585-1-Ig) or rabbit polyclonal antibody (17804-1-AP) can be used at dilutions of 1:50-1:500 for immunofluorescence .

• ER Morphology Changes: During ER stress, the organelle undergoes morphological changes that can be visualized using CALU as an ER marker. Immunofluorescence protocols using CALU antibodies at 1:50-1:200 dilutions can help document these structural alterations .

• Protein Expression Dynamics: Western blotting with CALU antibodies at 1:500-1:4000 dilutions can track changes in CALU expression levels during different phases of ER stress, potentially revealing regulation patterns correlated with the unfolded protein response .

• Calcium Homeostasis: As a calcium-binding protein, CALU may play a role in calcium homeostasis during ER stress. Combining CALU immunofluorescence with calcium imaging techniques can provide insights into this relationship.

• Secretory Pathway Analysis: CALU has been implicated in protein sorting and secretion. Using CALU antibodies in combination with secretory protein tracking can reveal alterations in the secretory pathway during ER stress conditions.

• Tissue-Specific Responses: Immunohistochemistry using CALU antibodies at 1:50-1:1000 dilutions can reveal tissue-specific patterns of ER stress responses in disease models, particularly in cancer tissues where CALU expression has been shown to be altered .

What are the best approaches for studying CALU post-translational modifications?

Investigating post-translational modifications (PTMs) of CALU requires specialized techniques:

• Phosphorylation Studies:

  • Use phospho-specific antibodies if available

  • Combine with phosphatase inhibitor cocktails during protein extraction

  • Consider phospho-enrichment techniques prior to Western blotting

  • Run parallel samples with and without phosphatase treatment

• Glycosylation Analysis:

  • Treat samples with glycosidases (PNGase F for N-linked, O-glycosidase for O-linked glycans)

  • Compare mobility shifts on Western blots using CALU antibodies at 1:500-1:2000 dilutions

  • Consider lectin affinity purification followed by CALU immunoblotting

• Calcium-Binding Studies:

  • Use mobility shift assays with varying calcium concentrations

  • Compare CALU detection in calcium-depleted versus calcium-rich conditions

• Proteomics Approaches:

  • Immunoprecipitate CALU using validated antibodies

  • Subject immunoprecipitated material to mass spectrometry analysis

  • Focus on identifying specific PTM sites and their occupancy

• Subcellular Fractionation:

  • Separate cellular components (membrane, cytosol, ER) before Western blotting

  • Compare CALU detection and mobility across fractions to identify compartment-specific modifications

• 2D Gel Electrophoresis:

  • Separate proteins by isoelectric point and molecular weight

  • Detect CALU using validated antibodies

  • Identify PTM-specific isoforms by their distinct migration patterns

The observed molecular weight of CALU (47-57 kDa) compared to its calculated molecular weight (37 kDa) suggests significant post-translational modifications that contribute to its function . These approaches can help characterize these modifications and their functional significance.